Wedbush Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $8

Wedbush downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Neutral and lowers the price target from $25 to $8.

Benzinga · 11/11/2019 11:55

Wedbush downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Neutral and lowers the price target from $25 to $8.